Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Wedbush restated their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Tuesday morning,RTT News reports. The firm currently has a $40.00 price objective on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

A number of other research analysts have also issued reports on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. TD Cowen began coverage on Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Up 5.5 %

Shares of ORKA opened at $22.30 on Tuesday. The firm has a market cap of $26.98 million, a PE ratio of -3.48 and a beta of 0.87. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88. The firm has a fifty day moving average price of $26.62.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the third quarter valued at $343,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $1,037,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at about $2,013,000. Janus Henderson Group PLC purchased a new position in Oruka Therapeutics during the 3rd quarter valued at about $5,840,000. Finally, Redmile Group LLC acquired a new position in Oruka Therapeutics during the third quarter worth about $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.